FDA Adds Vision-Risk Warning to Weight-Loss Drugs
Published on Honduras Daily · Nov 14, 2026 · Originally reported November 13, 2026 by Once Noticias
US health authorities are updating safety labels on GLP-1 drugs used for diabetes and weight loss after finding 6.4 cases of optic neuropathy per 100,000 users in clinical trials, prompting doctors to warn against unsupervised use.
An auto-translated English version isn’t available for Once Noticias, so this opens the original in Spanish. Honduras Daily curates and summarizes; the reporting is theirs.